lipo-c dosage FAQ

Increase B12 slightly but keep methionine constant to avoid pushing homocysteine higher through increased SAMe flux. Elevated baseline homocysteine (>15 µmol/L) signals impaired methionine synthase activity, often due to B12 deficiency or genetic MTHFR polymorphisms. In this case, 1.0 mL of standard formulation (1000mcg B12) twice weekly may be more effective than 0.5 mL, because the limiting factor is cofactor availability, not substrate. Monitor plasma homocysteine at weeks 2 and 4. If levels don't decrease by at least 20%, the protocol may require standalone methylfolate co-administration to support the methionine synthase cycle fully.

Monitor for nausea, headache, or gastrointestinal discomfort over the next 24–48 hours. These are symptoms of acute methionine overload as excess substrate converts to homocysteine. Increase water intake to support renal clearance and skip the next scheduled injection to allow plasma methyl donor levels to normalize. A single 3ml dose won't cause lasting harm in healthy individuals, but repeated overdosing elevates homocysteine chronically, which correlates with endothelial dysfunction and increased cardiovascular risk. Return to 1–2ml weekly and do not attempt to 'make up' the missed dose by increasing subsequent injections.

Discard any reconstituted LIPO-C solution that appears cloudy, contains visible particulates, or shows discoloration (yellow or brown tint). These are signs of bacterial contamination, oxidative degradation, or improper reconstitution technique. Properly reconstituted LIPO-C should be clear and colorless. Use bacteriostatic water (0.9% benzyl alcohol) for reconstitution, inject the diluent slowly down the side of the vial to avoid foaming, and refrigerate immediately at 2–8°C. Temperature excursions above 8°C accelerate oxidative breakdown of methionine and choline, rendering the compound ineffective.

Administer the missed dose as soon as you remember if fewer than 4 days have passed, then resume your regular schedule. If more than 4 days have passed, skip the missed dose and continue with your next scheduled injection. Do not double-dose to compensate. Inositol has a relatively short half-life (approximately 6–8 hours in circulation), so missing a single dose doesn't create lasting gaps in phosphatidylinositol synthesis, but doubling up can cause transient GI distress as excess inositol is renally cleared.

Recalculate injection volume using the existing concentration. Do not reconstitute a new vial unless the current one is depleted or expired. If your protocol increases from 12.5mg to 18.75mg and your vial is 10mg/mL, the new volume is 18.75mg ÷ 10mg/mL = 1.875mL (187.5 units). The concentration doesn't change because you're not adding more water. You're simply drawing a larger volume per injection. This approach works until the vial runs out; at that point, reconstitute the next vial using the same 5mL volume to maintain consistent 10mg/mL concentration across batches.

Convert millilitres to units using the 1mL = 100 units standard for U-100 insulin syringes. A calculated 0.6mL dose equals 60 units; 1.35mL equals 135 units. Write the unit equivalent on your protocol sheet to avoid recalculating before every injection. If your dose falls between unit markings (e.g., 1.23mL = 123 units), round to the nearest marking your syringe allows. Most U-100 syringes have 2-unit increments, so 123 units rounds to 122 or 124. This introduces negligible variance (under 2%) that doesn't meaningfully affect research outcomes when applied consistently.

You've diluted the solution below intended concentration. Recalculate before proceeding. If you added 7mL instead of 5mL to a 50mg vial, concentration drops to 50mg ÷ 7mL = 7.14mg/mL. To deliver 12.5mg, you now need 12.5mg ÷ 7.14mg/mL = 1.75mL per injection instead of 1.25mL. The compound isn't ruined, but you'll deplete the vial faster because each dose requires more volume. If the over-diluted volume exceeds your syringe capacity or comfortable injection limits, the vial may not support your full protocol. Consider this when deciding whether to discard and start fresh or proceed with adjusted volumes.

Inject your next scheduled dose in the fasted state and continue your regular protocol. Do not double-dose to compensate. The methionine and choline will still be absorbed, but hepatic lipid oxidation will be suppressed by elevated insulin levels, reducing the lipotropic effect by approximately 65%. One mistimed injection does not negate your overall protocol, but repeated postprandial administration will produce minimal metabolic benefit regardless of dose.

Your protocol will still show measurable lipotropic activity, but enzymatic saturation will be incomplete. At 1000mcg, methionine synthase operates below maximum velocity, which slows SAMe regeneration and constrains phosphatidylcholine synthesis. Research data shows this translates to roughly half the hepatic fat reduction compared to 5000mcg protocols over equivalent timeframes. If your research model tolerates longer observation periods, 1000mcg dosing may eventually reach similar endpoints. It just takes longer to get there.

Stop immediately if AST or ALT rises more than 20% from baseline. Elevated liver enzymes during LIPO-C use indicate either pre-existing hepatic stress (undiagnosed fatty liver, alcohol use, concurrent hepatotoxic medications) or methyl donor oversaturation exceeding hepatic processing capacity. Retest liver enzymes four weeks after discontinuation. If they normalise, LIPO-C was not the cause but revealed an underlying issue.

If you miss a dose by fewer than 48 hours, administer it as soon as you remember (in the fasted state) and continue your regular schedule. If more than 48 hours have passed, skip the missed dose entirely and resume on your next scheduled injection day. Do not administer two doses within 72 hours. Excessive methionine load without adequate spacing between doses increases homocysteine accumulation risk and provides no additional metabolic benefit.

Phase separation in LIPO-C solutions indicates incomplete mixing or pH incompatibility between components. Methylcobalamin is pH-sensitive and can precipitate if the reconstitution solvent's pH falls below 5.0 or exceeds 7.5. Use bacteriostatic water with a neutral pH (6.5–7.0) and inject the solvent slowly along the vial wall to avoid turbulence. If separation persists after gentle swirling, the formulation may have degraded during storage. Discard it and prepare a fresh batch. Injecting a separated solution results in inconsistent compound delivery and unpredictable dosing.

Discard the vial. Do not use it. Methionine oxidizes to methionine sulfoxide at temperatures above 8°C, and this conversion is irreversible and undetectable by appearance. A room-temperature excursion of 8–12 hours at 20–25°C can oxidize 40–60% of the methionine content, rendering the formulation partially or completely inactive. The financial loss of one vial is preferable to injecting an ineffective compound for weeks without knowing it.

Reduce LIPO-C to 0.75mL weekly if using semaglutide, tirzepatide, or liraglutide. GLP-1 agonists extend gastric emptying and prolong the postprandial insulin phase by 90–120 minutes beyond normal, which reduces the daily window where the liver is in a fat-exporting state. Lower doses prevent methyl donor oversaturation during insulin-dominant periods while still supporting hepatic function during the limited fasting windows GLP-1 therapy allows.

Mild nausea within 30–60 minutes post-injection is common and typically resolves within 2–3 hours. Sulfur-smelling breath indicates methionine metabolism to dimethyl sulfide, a normal volatile byproduct that clears within 6–8 hours. If nausea is severe or persistent beyond 4 hours, reduce your next dose by 25% and reassess tolerability. Persistent nausea at reduced dosing suggests methionine intolerance or concurrent gastrointestinal pathology. Consult a healthcare provider before continuing the protocol.

Pre-existing B12 sufficiency doesn't eliminate the need for exogenous methylcobalamin in LIPO-C protocols. The goal isn't correcting deficiency. It's saturating methionine synthase to maximise SAMe production rates. Even models with adequate baseline B12 show improved lipotropic outcomes when methylcobalamin is dosed at 5000mcg because the enzymatic demand during active lipid mobilisation exceeds normal physiological supply. Think of it as substrate loading rather than deficiency correction.

No. Administer the missed dose as soon as you remember if fewer than 5 days have passed, then resume your regular weekly schedule. If more than 5 days have passed, skip the missed dose and continue with your next scheduled injection. Doubling the dose does not compensate for the missed week and increases the risk of excess methionine metabolism to homocysteine, which can elevate inflammatory markers. LIPO-C works through sustained lipotropic substrate availability, not bolus dosing.

This typically indicates one of three scenarios: (1) the lipotropic dose is insufficient for your hepatic lipid load. Titrate to 2mL weekly under medical supervision; (2) dietary or metabolic factors are overwhelming the lipotropic pathway. Assess carbohydrate intake, insulin resistance, and alcohol consumption; (3) the reconstituted solution was stored incorrectly and lost potency. Lipotropic response is dose-dependent and individual. Some patients require 2mL weekly to produce the same ALT reduction others achieve at 1mL.

Increase to 1mL weekly and administer in a true fasted state (12+ hours, no caloric intake including coffee with cream). Most perceived LIPO-C failures result from administering the compound too close to a meal, which shifts the liver into glycogen storage mode and blunts methyl donor utilisation for fat export. If fatigue persists after two weeks at 1mL, verify that you're in a genuine caloric deficit. LIPO-C supports energy during restriction by preventing hepatic fat accumulation, but it cannot create energy output from surplus intake.

Discard it. Methylcobalamin degrades irreversibly above 8°C. A single temperature excursion overnight (8–12 hours at room temperature) reduces B12 bioavailability by 40–60%, turning the solution into an expensive saline injection with diminished methyl donor potency. Refrigeration is non-negotiable post-reconstitution.